A number of other analysts also recently commented on the stock. Oppenheimer dropped their price target on shares of Cellectar Biosciences from $47.00 to $12.00 in a research report on Friday, November 4th. Maxim Group lowered their price objective on shares of Cellectar Biosciences to $7.00 in a research note on Tuesday, November 15th. Finally, HC Wainwright lifted their price objective on shares of Cellectar Biosciences from $3.00 to $4.00 and gave the stock a buy rating in a research note on Friday, November 4th.
Cellectar Biosciences Trading Down 1.1 %
CLRB stock opened at $1.88 on Monday. Cellectar Biosciences has a 52 week low of $1.75 and a 52 week high of $7.90. The company has a market capitalization of $17.65 million, a price-to-earnings ratio of -0.42 and a beta of 1.19. The firm’s 50-day moving average is $2.59 and its two-hundred day moving average is $3.87.
Hedge Funds Weigh In On Cellectar Biosciences
About Cellectar Biosciences
Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM.
- Get a free copy of the StockNews.com research report on Cellectar Biosciences (CLRB)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.